Equities

Haw Par Corporation Ltd

Haw Par Corporation Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SGD)9.80
  • Today's Change0.17 / 1.77%
  • Shares traded26.40k
  • 1 Year change+4.14%
  • Beta0.5929
Data delayed at least 10 minutes, as of May 16 2024 02:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haw Par Corporation Limited is a Singapore-based holding company. The principal activities of the Company are licensing of the Tiger trademarks and owning and holding investments for the long-term. Its segments include Healthcare products, Investments and Others. The Company's Healthcare products segment is engaged in manufacturing and distributing topical analgesic products under the Tiger Balm and Kwan Loong brand. Its Investments segment is engaged in long term investing activities, mainly in quoted securities in Asia. The Company's Others segment includes property division, which owns and leases out several investment properties in Asia, and leisure division, which provides family and tourist-oriented leisure activities in the form of oceanariums. Its Tiger Balm brand products include Tiger Balm White Ointment, Tiger Balm Muscle Rub, Tiger Balm Back Pain Patch and Tiger Balm Muscle Rub. Its Kwan Loong brand products include Kwan Loong Medicated and Oil Kwan Loong Refresher.

  • Revenue in SGD (TTM)232.06m
  • Net income in SGD216.57m
  • Incorporated1969
  • Employees595.00
  • Location
    Haw Par Corporation Ltd401 Commonwealth Drive#03-03 Haw Par Techno Centre 149598SingaporeSGP
  • Phone+65 63379102
  • Fax+65 63369232
  • Websitehttps://www.hawpar.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jinyu Bio-Technology Co Ltd295.67m52.80m2.06bn1.65k37.941.95--6.950.25880.25881.445.050.23652.061.98956,543.204.094.824.795.6857.9758.7817.2819.913.33--0.004336.414.55-3.3734.63-17.77-12.92-25.56
Haw Par Corporation Ltd232.06m216.57m2.16bn595.009.970.62099.709.300.97840.97841.0515.700.06415.086.16--5.984.736.164.8558.1354.4293.3285.355.35--0.00845.5727.44-0.488546.023.8818.245.92
Joinn Laboratories China Co Ltd435.80m-11.77m2.20bn2.50k--1.58--5.06-0.0862-0.08623.1210.750.230.69068.14---0.68568.99-0.821911.0739.4646.76-2.9832.013.510.99960.007923.794.7842.20-63.0429.668.2123.46
Liaoning Chengda Biotechnology Co Ltd329.16m78.56m2.21bn1.73k27.981.21--6.711.011.014.2623.410.17430.70611.611,016,911.004.1610.634.2711.0181.4885.7423.8739.5620.80--0.00231.53-3.584.71-34.75-5.5639.78--
Astrazeneca Pharma India Ltd193.82m22.55m2.21bn947.0097.95--88.1811.4055.7255.72478.78--------12,640,230.00--10.51--18.1059.9358.0511.649.11--132.84--11.8224.5011.8961.1930.826.29--
Polaris Group312.80k-65.92m2.21bn----7.18--7,075.03-2.12-2.120.01019.900.0008--2.68---17.38-16.55-18.91-17.96-40.97---21,281.41-12,960.215.28--0.1357--16.18---37.05--50.45--
Heilongjiang ZBD Pharmaceutical Co Ltd509.78m95.68m2.23bn2.55k23.241.52--4.370.54470.54472.908.350.21861.580.81341,071,832.004.063.485.614.7846.0938.9318.5610.082.35--0.286227.18-25.502.45155.000.4417-25.684.05
Jiangxi Tianxin Pharmaceutical Co Ltd336.09m96.21m2.23bn2.47k23.202.74--6.641.181.184.119.950.362.686.66727,792.6010.31--11.11--39.78--28.63--5.51--0.0551---18.34---23.51------
Sansure Biotech Inc224.80m71.90m2.23bn2.01k31.501.59--9.940.64480.64482.0612.770.13770.82741.41599,646.904.1426.744.6930.9774.8267.4730.0642.017.94--0.058922.40-84.3927.12-81.22121.8964.08--
Jiangsu Kanion Pharmaceutical Co., Ltd.910.93m101.54m2.25bn5.44k22.132.24--2.470.93420.93428.399.220.69153.506.92895,523.307.826.6810.549.4972.5574.0211.3110.282.23--0.0025.5711.884.9423.545.33-1.8735.99
Data as of May 16 2024. Currency figures normalised to Haw Par Corporation Ltd's reporting currency: Singapore Dollar SGD

Institutional shareholders

18.96%Per cent of shares held by top holders
HolderShares% Held
First Eagle Investment Management LLCas of 06 Mar 202323.35m10.55%
Kayne Anderson Rudnick Investment Management LLCas of 17 Aug 202311.22m5.07%
Asset Value Investors Ltd.as of 31 Jan 20241.86m0.84%
Dimensional Fund Advisors LPas of 28 Mar 20241.33m0.60%
Burgundy Asset Management Ltd.as of 30 Apr 2024945.70k0.43%
WCM Investment Management LLCas of 31 Dec 2023717.90k0.32%
Invesco Advisers, Inc.as of 31 Mar 2021715.40k0.32%
First Sentier Investors (Singapore)as of 31 Jan 2024695.30k0.31%
Healthinvest Partners ABas of 30 Jun 2022580.00k0.26%
State Board of Administration of Florida Retirement Systemas of 30 Jun 2023571.20k0.26%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.